JP6841753B2 - ヒストンｈ３−リジントリメチル化を除去することによって体細胞核移入（ｓｃｎｔ）効率を増加させるための方法および組成物 - Google Patents

ヒストンｈ３−リジントリメチル化を除去することによって体細胞核移入（ｓｃｎｔ）効率を増加させるための方法および組成物 Download PDF

Info

Publication number
JP6841753B2
JP6841753B2 JP2017514421A JP2017514421A JP6841753B2 JP 6841753 B2 JP6841753 B2 JP 6841753B2 JP 2017514421 A JP2017514421 A JP 2017514421A JP 2017514421 A JP2017514421 A JP 2017514421A JP 6841753 B2 JP6841753 B2 JP 6841753B2
Authority
JP
Japan
Prior art keywords
scnt
cell
human
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017514421A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528142A (ja
JP2017528142A5 (https=
Inventor
イー チャン
イー チャン
章悟 的場
章悟 的場
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2017528142A publication Critical patent/JP2017528142A/ja
Publication of JP2017528142A5 publication Critical patent/JP2017528142A5/ja
Application granted granted Critical
Publication of JP6841753B2 publication Critical patent/JP6841753B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C12N15/877—Techniques for producing new mammalian cloned embryos
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0273—Cloned vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0604—Whole embryos; Culture medium therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/04—Cells produced using nuclear transfer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01043—Histone-lysine N-methyltransferase (2.1.1.43)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2017514421A 2014-09-15 2015-09-15 ヒストンｈ３−リジントリメチル化を除去することによって体細胞核移入（ｓｃｎｔ）効率を増加させるための方法および組成物 Active JP6841753B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462050308P 2014-09-15 2014-09-15
US62/050,308 2014-09-15
US201462053514P 2014-09-22 2014-09-22
US62/053,514 2014-09-22
PCT/US2015/050178 WO2016044271A2 (en) 2014-09-15 2015-09-15 Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021023834A Division JP7277494B2 (ja) 2014-09-15 2021-02-18 ヒストンｈ３－リジントリメチル化を除去することによって体細胞核移入（ｓｃｎｔ）効率を増加させるための方法および組成物

Publications (3)

Publication Number Publication Date
JP2017528142A JP2017528142A (ja) 2017-09-28
JP2017528142A5 JP2017528142A5 (https=) 2018-11-01
JP6841753B2 true JP6841753B2 (ja) 2021-03-10

Family

ID=55534004

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017514421A Active JP6841753B2 (ja) 2014-09-15 2015-09-15 ヒストンｈ３−リジントリメチル化を除去することによって体細胞核移入（ｓｃｎｔ）効率を増加させるための方法および組成物
JP2021023834A Active JP7277494B2 (ja) 2014-09-15 2021-02-18 ヒストンｈ３－リジントリメチル化を除去することによって体細胞核移入（ｓｃｎｔ）効率を増加させるための方法および組成物
JP2023001284A Pending JP2023026679A (ja) 2014-09-15 2023-01-06 ヒストンｈ３－リジントリメチル化を除去することによって体細胞核移入（ｓｃｎｔ）効率を増加させるための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021023834A Active JP7277494B2 (ja) 2014-09-15 2021-02-18 ヒストンｈ３－リジントリメチル化を除去することによって体細胞核移入（ｓｃｎｔ）効率を増加させるための方法および組成物
JP2023001284A Pending JP2023026679A (ja) 2014-09-15 2023-01-06 ヒストンｈ３－リジントリメチル化を除去することによって体細胞核移入（ｓｃｎｔ）効率を増加させるための方法および組成物

Country Status (5)

Country Link
US (3) US11390885B2 (https=)
EP (1) EP3194581A4 (https=)
JP (3) JP6841753B2 (https=)
KR (2) KR102617137B1 (https=)
WO (1) WO2016044271A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044271A2 (en) 2014-09-15 2016-03-24 Children's Medical Center Corporation Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation
CN106591374B (zh) * 2016-12-30 2019-08-09 中国农业科学院北京畜牧兽医研究所 一种提高猪体细胞核移植胚胎发育效率的方法
CN106676136B (zh) * 2016-12-30 2019-11-29 中国农业科学院北京畜牧兽医研究所 一种提高猪体细胞核移植效率的方法
CN107299113A (zh) * 2017-06-12 2017-10-27 内蒙古大学 H3K27me3及其去甲基化酶KDM6A/B在小鼠核移植重构胚中的应用方法
CN108285906B (zh) * 2017-12-29 2021-07-09 温氏食品集团股份有限公司 一种定点整合外源dna转基因猪的构建方法
CN108624621B (zh) * 2018-01-17 2019-04-12 中国科学院上海生命科学研究院 非人灵长类的体细胞克隆动物的制备方法
JP7650661B2 (ja) * 2018-01-23 2025-03-25 チャ ユニバーシティ インダストリー－アカデミック コオペレーション ファンデーション Ｒａｄ５１活性化剤を含む胚芽発達用組成物、及びそれを利用して胚芽発達率を向上させる方法
KR20190089782A (ko) * 2018-01-23 2019-07-31 차의과학대학교 산학협력단 멜라토닌을 포함하는, 배아 발달용 조성물 및 이를 이용하여 배아 발달의 효율을 향상시키는 방법
AU2019247490A1 (en) * 2018-04-06 2020-10-22 Children's Medical Center Corporation Compositions and methods for somatic cell reprogramming and modulating imprinting
CN110547291A (zh) * 2019-09-27 2019-12-10 安徽医科大学 一种高效抗氧化的人卵母细胞冷冻保护剂
CN111466367B (zh) * 2020-02-17 2022-03-01 天津大学 用于保存细胞的组合物
KR102520268B1 (ko) * 2020-12-04 2023-04-12 대한민국 microRNA-148a 직접 주입을 통한 돼지 체세포 핵치환란의 발달율 향상 방법
CN113186152B (zh) * 2021-05-19 2023-05-26 南方医科大学 Dna甲基转移酶抑制剂在提高动物圆形精子注射胚胎发育效率中的应用
CN119162252B (zh) * 2024-11-20 2025-05-02 中国科学院昆明动物研究所 一种通过重构核移植囊胚提高克隆小鼠出生率的方法

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4441972A (en) 1983-04-08 1984-04-10 D.E.P. Systems, Inc. Apparatus for electrofusion of biological particles
US4664097A (en) 1984-05-09 1987-05-12 The Wistar Institute Of Anatomy & Biology Nuclear transplantation in the mammalian embryo by microsurgery and cell fusion
US4578168A (en) 1984-07-27 1986-03-25 Biotronics Apparatus for fusing live cells with electric fields
IL73883A (en) 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
JP3022967B2 (ja) 1985-03-15 2000-03-21 アンチバイラルズ インコーポレイテッド 立体規則性ポリヌクレオチド結合ポリマー
JPS6276624A (ja) * 1985-09-30 1987-04-08 Toshiba Corp レジスト剥離装置
US4994384A (en) 1986-12-31 1991-02-19 W. R. Grace & Co.-Conn. Multiplying bovine embryos
US5057420A (en) 1987-06-05 1991-10-15 Granada Biosciences, Inc. Bovine nuclear transplantation
US5213979A (en) 1987-12-30 1993-05-25 W. R. Grace & Co.-Conn. In vitro culture of bovine embryos
US6436701B1 (en) 1988-09-21 2002-08-20 Babraham Institute Derivation of pluripotential embryonic cell lines from ungulate species
US4944384A (en) 1989-01-30 1990-07-31 Hay & Forage Industries Trash discharge apparatus for crop transferring conveyor mechanism
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5580774A (en) 1989-07-31 1996-12-03 Eli Lilly And Company Chimeric antibodies directed against a human glycoprotein antigen
ATE269870T1 (de) 1989-10-24 2004-07-15 Isis Pharmaceuticals Inc 2'-modifizierte oligonukleotide
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
ATE174058T1 (de) 1989-11-06 1998-12-15 Cell Genesys Inc Herstellung von proteinen mittels homologer rekombination
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5223168A (en) 1989-12-12 1993-06-29 Gary Holt Surface cleaner and treatment
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
RU2128227C1 (ru) 1989-12-22 1999-03-27 Апплайд Резеч Системз АРС Холдинг Н.В. (NL) (Антильские острова) Способ активации транскрипционно-молчащего гена
US5506351A (en) 1992-07-23 1996-04-09 Isis Pharmaceuticals Process for the preparation of 2'-O-alkyl guanosine and related compounds
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5212295A (en) 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
WO1992001040A1 (en) 1990-07-09 1992-01-23 Amrad Corporation Limited Enhanced implantation, development and maintenance of embryos using leukaemia inhibitory factor
US5096822A (en) 1990-07-26 1992-03-17 W. R. Grace & Co.- Conn. Bovine embryo medium
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5223618A (en) 1990-08-13 1993-06-29 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analog compounds
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
BR9106702A (pt) 1990-07-27 1993-06-08 Isis Pharmaceuticals Inc Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US6262241B1 (en) 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
JP3104995B2 (ja) 1991-01-31 2000-10-30 ワーナー−ランバート・コンパニー 抗炎症剤として有用な４，６−ジ−第三ブチル−５−ヒドロキシ−１，３−ピリミジンの置換されたヘテロアリール類似体
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
EP1097945B1 (en) 1991-03-18 2007-07-04 New York University Monoclonal and chimeric antibody specific for human tumor necrosis factor
AU664847B2 (en) 1991-05-15 1995-12-07 Cell Genesys, Inc. Genomic modifications with homologous DNA targeting
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5173158A (en) 1991-07-22 1992-12-22 Schmukler Robert E Apparatus and methods for electroporation and electrofusion
US5599797A (en) 1991-10-15 1997-02-04 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US6107543A (en) 1992-08-20 2000-08-22 Infigen, Inc. Culture of totipotent embryonic inner cells mass cells and production of bovine animals
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US5858988A (en) 1993-02-24 1999-01-12 Wang; Jui H. Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
GB9304620D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Compounds
GB9308271D0 (en) 1993-04-21 1993-06-02 Univ Edinburgh Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US5571902A (en) 1993-07-29 1996-11-05 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5554746A (en) 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5705629A (en) 1995-10-20 1998-01-06 Hybridon, Inc. Methods for H-phosphonate synthesis of mono- and oligonucleotides
JPH09260337A (ja) * 1996-03-26 1997-10-03 Nikon Corp 薄膜構造体の製造装置
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
US6011197A (en) 1997-03-06 2000-01-04 Infigen, Inc. Method of cloning bovines using reprogrammed non-embryonic bovine cells
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
JP2995179B1 (ja) * 1998-07-31 1999-12-27 茂徳科技股▲ふん▼有限公司 浸漬液恒温供給システム
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US7612250B2 (en) 2002-07-29 2009-11-03 Trustees Of Tufts College Nuclear transfer embryo formation method
CA2501415A1 (en) 2002-08-01 2004-02-12 Gtc Biotherapeutics, Inc. Method of selecting cells for somatic cell nuclear transfer
CN1735338A (zh) 2002-12-10 2006-02-15 Gtc生物治疗学公司 利用体细胞核转移胚胎作为细胞供体进行附加核转移的方法和系统
KR20060057528A (ko) 2003-04-09 2006-05-26 마제-위민스 헬스 코퍼레이션 동물에서 체세포 핵 전이와 연관된 유사분열 방추 결함을교정하는 방법
US8807129B2 (en) 2004-08-10 2014-08-19 Kevin Keith Mackamul Tracker drive system and solar energy collection system
CA3015835A1 (en) 2004-11-04 2006-05-18 Astellas Institute For Regenerative Medicine Derivation of embryonic stem cells
WO2006116803A1 (en) * 2005-04-29 2006-11-09 Innovative Dairy Products Pty Ltd As Trustee For The Participants Of The Cooperative Research Centre For Innovative Dairy Products A method for producing stem cells or stem cell-like cells from mammalian embryos
EP3611266B1 (en) 2005-08-23 2022-11-09 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
JP2007117081A (ja) * 2005-09-30 2007-05-17 Institute Of Physical & Chemical Research 核移植卵子の作製方法
CA2597840A1 (en) 2006-09-01 2008-03-01 Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services Methods and compositions for the treatment and prevention of cancer
CN101514878B (zh) * 2008-02-18 2010-09-29 扬博科技股份有限公司 用于基板制程的热交换系统
WO2009134418A2 (en) 2008-04-30 2009-11-05 Fox Chase Cancer Center Assay for identifying agents that modulate epigenetic silencing, and agents identified thereby
US20110136145A1 (en) 2008-05-22 2011-06-09 The Johns Hopkins University Methods for promoting fusion and reprogramming of somatic cells
WO2010033920A2 (en) * 2008-09-19 2010-03-25 Whitehead Institute For Biomedical Research Compositions and methods for enhancing cell reprogramming
DE102009039097B3 (de) 2009-08-27 2010-11-25 Siemens Aktiengesellschaft Verfahren zum Übertragen von Daten in einem Sensornetzwerk, Sensorknoten und Zentral-Rechner
US20130189780A1 (en) 2009-12-31 2013-07-25 Fate Therapeutics, Inc. Reprogramming compositions
CA2796464C (en) 2010-04-16 2021-08-03 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
WO2012005769A1 (en) 2010-07-09 2012-01-12 Telecommunication Systems, Inc. Location privacy selector
CN201768705U (zh) * 2010-08-18 2011-03-23 州巧科技股份有限公司 节能清洗系统
WO2012027531A1 (en) 2010-08-25 2012-03-01 Access Business Group International Llc Wireless power supply system and multi-layer shim assembly
WO2012029957A1 (ja) 2010-09-03 2012-03-08 独立行政法人理化学研究所 クローン動物の作出方法
KR101290029B1 (ko) 2011-01-20 2013-07-30 에스티팜 주식회사 시타글립틴의 중간체 제조방법
EP2714903B1 (en) 2011-06-03 2018-03-21 OncoTherapy Science, Inc. Suv39h2 as a target gene for cancer therapy
WO2013050405A1 (en) 2011-10-03 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of th2 mediated diseases
US20140161785A1 (en) 2012-12-10 2014-06-12 Feiyan Liu Verticillin A Inhibition of Histone Methyltransferases
JP6290931B2 (ja) 2013-02-15 2018-03-07 ソン クヮン メデイカル ファウンデーション 体細胞核移植を利用する単為生殖幹細胞および患者特異的ヒト胚幹細胞の製造法
WO2014197835A2 (en) 2013-06-06 2014-12-11 The General Hospital Corporation Methods and compositions for the treatment of cancer
WO2016044271A2 (en) 2014-09-15 2016-03-24 Children's Medical Center Corporation Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation
EP3359167A4 (en) 2015-10-09 2019-11-13 Children's Medical Center Corporation METHOD AND COMPOSITIONS FOR INCREASING HUMAN SOMATIC CELL CORE TRANSFER EFFICIENCY BY REMOVING HISTON-H3-LYSINE TRIMETHYLATION AND DERIVING FROM HUMAN NT-ESC
WO2018073787A2 (en) 2016-10-19 2018-04-26 Fred Hutchinson Cancer Research Center Compositions and methods for reprogramming cells and for somatic cell nuclear transfer using duxc expression
CN107299113A (zh) 2017-06-12 2017-10-27 内蒙古大学 H3K27me3及其去甲基化酶KDM6A/B在小鼠核移植重构胚中的应用方法
EP3654956A4 (en) 2017-07-19 2021-04-28 Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH IMPRESSION DEFECTS
AU2019247490A1 (en) 2018-04-06 2020-10-22 Children's Medical Center Corporation Compositions and methods for somatic cell reprogramming and modulating imprinting
WO2020018106A1 (en) 2018-07-19 2020-01-23 Children's Medical Center Corporation Compositions and methods for generating physiological x chromosome inactivation
JP3224832U (ja) * 2019-11-06 2020-01-23 揚▲博▼科技股▲分▼有限公司 基板エッチング処理装置における制御ボックスの散熱装置
JP7631092B2 (ja) * 2021-05-19 2025-02-18 株式会社Ｓｃｒｅｅｎホールディングス 基板処理システム

Also Published As

Publication number Publication date
KR20170120089A (ko) 2017-10-30
US20180363008A1 (en) 2018-12-20
KR102617137B1 (ko) 2023-12-27
JP7277494B2 (ja) 2023-05-19
JP2017528142A (ja) 2017-09-28
KR20220165807A (ko) 2022-12-15
WO2016044271A3 (en) 2016-05-19
US20230015276A1 (en) 2023-01-19
US20170327846A1 (en) 2017-11-16
WO2016044271A2 (en) 2016-03-24
EP3194581A4 (en) 2018-04-25
US10266848B2 (en) 2019-04-23
JP2021074023A (ja) 2021-05-20
KR102473092B1 (ko) 2022-12-01
EP3194581A2 (en) 2017-07-26
US11390885B2 (en) 2022-07-19
JP2023026679A (ja) 2023-02-24

Similar Documents

Publication Publication Date Title
JP7277494B2 (ja) ヒストンｈ３－リジントリメチル化を除去することによって体細胞核移入（ｓｃｎｔ）効率を増加させるための方法および組成物
US20200181648A1 (en) Methods and compositions to increase human somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation, and derivation of human nt-esc
ES2831424T3 (es) Células madre pluripotentes naif aisladas y métodos para generarlas
CN112272516B (zh) 用于体细胞重新编程和调整印记的组合物和方法
JP7762490B2 (ja) 細胞リプログラミングのための組成物および方法
CN118973388A (zh) 胚胎干细胞的基因编辑方法
HK40007627A (en) Methods and compositions to increase human somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation, and derivation of human nt-esc
CN118974253A (zh) Crispr v型系统的治疗应用
HK40047167B (en) Compositions and methods for somatic cell reprogramming and modulating imprinting
HK40047167A (en) Compositions and methods for somatic cell reprogramming and modulating imprinting
Oh Reprogramming Pluripotent Stem Cell Towards Totipotency
Adams The knockdown of Dnmt1 using small inhibitory RNA: a method to assist in the reprogramming of a donor genome during nuclear transfer
Wilson MicroRNA-mediated silencing of bovine NANOG and MBD3

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190718

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201022

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210218

R150 Certificate of patent or registration of utility model

Ref document number: 6841753

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250